非小细胞肺癌免疫检查点阻断治疗期间新抗原 landscape 的演变
本研究分析了非小细胞肺癌患者在接受抗PD-1或抗PD-1/抗CTLA-4抗体治疗获得初始缓解后出现获得性耐药时肿瘤新抗原的演变。配对分析治疗前与耐药后肿瘤发现,耐药克隆中7至18个推定突变相关新抗原丢失,这些新抗原来源的肽段可在自体T细胞培养中引发克隆性T细胞扩增。新抗原丢失通过消除肿瘤亚克隆或删除含主干变异的染色体区域发生,并与T细胞受体克隆性变化相关。
要点
- 耐药克隆中7至18个推定突变相关新抗原丢失
- 丢失的新抗原肽段可在自体T细胞培养中引发克隆性T细胞扩增
- 新抗原丢失与T细胞受体克隆性变化相关
核心结论
- 非小细胞肺癌免疫检查点阻断获得性耐药可伴随突变 landscape 演变发生,其中部分突变编码可被T细胞识别的肿瘤新抗原。
- 作者认为,拓宽新抗原反应性的广度可能减轻获得性耐药的发生。
研究设计与样本
- 研究分析非小细胞肺癌患者接受抗PD-1或抗PD-1/抗CTLA-4抗体免疫检查点阻断初始缓解后出现获得性耐药时肿瘤新抗原的演变。
- 对配对的治疗前与耐药后肿瘤进行分析。
主要发现
- 配对分析发现,耐药克隆中7至18个推定突变相关新抗原丢失。
- 从被消除的新抗原生成的肽段在自体T细胞培养中引发克隆性T细胞扩增,提示其产生了功能性免疫反应。
- 新抗原丢失通过消除肿瘤亚克隆或删除含主干变异的染色体区域发生,并与T细胞受体克隆性变化相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in patients with non-small cell lung cancer after initial response to immune checkpoint blockade with anti-PD-1 or anti-PD-1/anti-CTLA-4 antibodies. Analyses of matched pretreatment and resistant tumors identified genomic changes resulting in loss of 7 to 18 putative mutation-associated neoantigens in resistant clones. Peptides generated from the eliminated neoantigens elicited clonal T-cell expansion in autologous T-cell cultures, suggesting that they generated functional immune responses. Neoantigen loss occurred through elimination of tumor subclones or through deletion of chromosomal regions containing truncal alterations, and was associated with changes in T-cell receptor clonality. These analyses provide insight into the dynamics of mutational landscapes during immune checkpoint blockade and have implications for the development of immune therapies that target tumor neoantigens.Significance: Acquired resistance to immune checkpoint therapy is being recognized more commonly. This work demonstrates for the first time that acquired resistance to immune checkpoint blockade can arise in association with the evolving landscape of mutations, some of which encode tumor neoantigens recognizable by T cells. These observations imply that widening the breadth of neoantigen reactivity may mitigate the development of acquired resistance. Cancer Discov; 7(3); 264-76. ©2017 AACR.See related commentary by Yang, p. 250This article is highlighted in the In This Issue feature, p. 235.
引用
- Anagnostou V, Smith KN, Forde PM, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2016. PMID: 28031159. doi:10.1158/2159-8290.CD-16-0828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。